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Abstract
Tylosis (hyperkeratosis palmaris et plantaris) is characterised by focal thickening of the skin of the hands and feet
and is associated with a very high lifetime risk of developing squamous cell carcinoma of the oesophagus. This risk
has been calculated to be 95 % at the age of 65 in one large family, however the frequency of the disorder in the
general population is not known and is likely to be less than one in 1,000,000. Oesophageal lesions appear as small
(2–5 mm), white, polyploid lesions dotted throughout the oesophagus and oral leukokeratosis has also been described.
Although symptoms of oesophageal cancer can include dysphagia, odynophagia, anorexia and weight loss, there may
be an absence of symptoms in early disease, highlighting the importance of endoscopic surveillance in these patients.
Oesophageal cancer associated with tylosis usually presents in middle to late life (from mid-fifties onwards) and shows
no earlier development than the sporadic form of the disease. Tylosis with oesophageal cancer is inherited as
an autosomal dominant trait with complete penetrance of the cutaneous features, usually by 7 to 8 years of
age but can present as late as puberty. Mutations in RHBDF2 located on 17q25.1 have recently been found to
be causative. A diagnosis of tylosis with oesophageal cancer is made on the basis of a positive family history,
characteristic clinical features, including cutaneous and oesophageal lesions, and genetic analysis for mutations in RHBDF2.
The key management goal is surveillance for early detection and treatment of oesophageal dysplasia. Surveillance
includes annual gastroscopy with biopsy of any suspicious lesion together with quadratic biopsies from the
upper, middle and lower oesophagus. This is coupled with dietary and lifestyle modification advice and symptom
education. Symptomatic management of the palmoplantar keratoderma includes regular application of emollients,
specialist footwear and early treatment of fissures and super-added infection, particularly tinea pedis. More specific
treatment for the thick skin is available in the form of oral retinoids, which are very effective but commonly produce
side effects, including nasal excoriation and bleeding, hypercholesterolaemia, and abnormal liver function tests. Genetic
counselling can be offered to patients and family members once a family history has been established. The prognosis
of tylosis with oesophageal cancer is difficult to determine due to the limited number of affected individuals. In the last
40 years of surveillance, five out of six cases of squamous oesophageal cancer in the Liverpool family were detected
endoscopically and were surgically removed. Four of five patients had stage 1 disease at presentation and remain alive
and well more than 8 years later. This suggests that the presence of a screening program improves prognosis for
these patients.
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Introduction
This review summarizes current diagnostic, management
and treatment practices for the rare genetic disorder tylo-
sis with oesophageal cancer in the context of the current
understanding of the molecular basis for this disease. This
review is intended for a general audience with an interest
in this rare form of familial cancer from a clinical or bio-
medical perspective. The disease has commonly been di-
agnosed following observation of the tylosis skin condition
and a family history, but more recent advances in DNA
based diagnosis has allowed a more objective approach. Fi-
nally, we discuss unresolved issues, highlighting the early
stage of research into the molecular processes underpin-
ning this disorder.
Disease name/synonyms
Tylosis with esophageal cancer (TOC) (OMIM 148500)
Tylosis - oesophageal carcinoma
Palmoplantar hyperkeratosis-esophageal carcinoma syn-
drome (ORPHA2198)
Palmoplantar keratoderma with oesophageal cancer
Clarke-Howell-Evans-McConnell syndrome
Howell-Evans syndrome
Bennion-Patterson syndrome
Keratosis palmaris et plantaris with oesophageal cancer
Keratosis palmoplantaris-esophageal carcinoma syndrome
Definition
Tylosis with oesophageal cancer is characterised by
thickening of the skin of the hands and feet (focal,
non-epidermolytic form of palmoplantar keratoderma)
associated with a very high lifetime risk of developing
squamous cell carcinoma of the oesophagus (OSCC).
Epidemiology
Tylosis with oesophageal cancer was first described in two
large Liverpool (UK) families [1], the larger of which was
reviewed in 1994 [2]. At that stage, 345 family members
had been identified, 89 of whom had been diagnosed with
tylosis with 57 still alive. It has since been determined that
the two Liverpool families are in fact distant kindreds [3].
Similar but smaller pedigrees have been reported from
Germany [4] the United States [5] Finland [6] Spain [7]
and Brazil [8]. The prevalence of the disorder in the gen-
eral population is unknown, but is likely to be less than
one in 1,000,000.
Clinical description
Tylosis (hyperkeratosis palmaris et plantaris) is a focal,
non-epidermolytic form of keratoderma characterised by
areas of yellowish thickened plaques restricted to areas
of weight bearing and/or friction on the palms and soles
[5, 9]. The cutaneous features are completely penetrant
and are usually evident by 7 to 8 years of age but can
present as late as puberty [2]. The skin lesions can be com-
plicated by discomfort, fissuring and infection and may
also include follicular papules and cutaneous horns.
Oesophageal lesions present as small (2–5 mm), white,
polyploid lesions dotted throughout the oesophagus (Fig. 1).
The number and size of these varies between individuals,
but does not worsen with age or prior to the development
of carcinomas. In addition, oral leukokeratosis has been
described, [10, 11]. Although the oral lesions are cons-
idered to be largely benign, two cases of squamous cancer
of the oropharynx have been recorded (Ellis, personal
observation).
A total of 21 out of 89 members of the Liverpool kindred
reviewed in 1994 [2] had died of oesophageal neoplasia and
11 had died of other causes. The risk of developing
oesophageal cancer in the Liverpool family was calculated
to be 95 % at the age of 65. However, in this small sample
size, the age of presentation in individuals with tylosis is
not significantly lower than that for oesophageal squ-
amous cell carcinoma (OSCC) in the general population
(Ellis, personal communication), nor is distant metastasis
more or less prevalent. There is no known increase in the
incidence of other common carcinomas in these patients.
Fig. 1 Benign oesophageal lesions in individuals from the Liverpool tyosis with oesophageal cancer family. a oesophageal lesions in a 32 year old
female using conventional imaging; b oesophageal lesions in a 61 year old male using narrow band imaging
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Symptoms of oesophageal cancer can include dysphagia,
odynophagia, anorexia and weight loss. Initially the sensa-
tion of obstruction is only for solid food such as bread or
meat and later it is also for softer food. In the later stages
the patient has difficulty swallowing even liquids. The
patient can lose their appetite or become afraid to eat (sito-
phobia) and they lose weight. If the site of the blockage is
in the upper oesophagus the patient may choke or start
coughing on swallowing due to inhalation of food and
subsequently develop chest infections. Less commonly the
condition may present due to spread elsewhere such as the
lungs (breathlessness, cough), liver (jaundice, abdominal
swelling due to fluid, ascites), bones (pain or unexpected
fractures) or local lymph nodes (glandular swellings in the
neck). However there may be an absence of symptoms,
highlighting the importance of endoscopic surveillance in
these patients.
Aetiology
Tylosis with oesophageal cancer is inherited as an auto-
somal dominant trait with complete penetrance. Following
linkage mapping and targeted next generation sequencing,
missense mutations have been described in RHBDF2 lo-
cated on 17q25.1, which encodes an inactive rhomboid
protein, iRhom2 [12], that plays a role in EGFR shedding.
It is likely that aberrant EGFR signalling underlies the pro-
pensity for oesophageal carcinoma [13].
Diagnosis and diagnostic methods
A diagnosis of tylosis with oesophageal cancer is made on
the basis of a positive family history, characteristic clinical
features, including focal palmar and plantar hyperkeratosis
and oesophageal lesions, and mutations in RHBDF2.
Oesophageal biopsies taken from individuals diagnosed
with tylosis prior to the onset of oesophageal cancer do
not have any specific distinctive features but tend to have
prominent keratohyaline granules, inflammatory cell infil-
trate and parakeratosis [14]. Histological features of the
affected skin include acanthosis, hyperkeratosis and hyp-
ergranulosis but no parakeratosis or spongiosis. To date,
three disease-associated missense mutations in RHBDF2
have been identified:c.557 T→C (p.Ile186Thr), c.566C→
T (p.Pro189Leu) and c.562 G→A (p.Asp188Asn) [6, 12].
Squamous cell oesophageal cancer associated with tylo-
sis usually presents in middle to late life (from mid-fifties
onwards) at a similar age to that of sporadic OSCC. The
diagnosis is made by performing an oesophagogastroscopy
(fibreoptic examination of the gullet and stomach) with
biopsies taken of the tumour to establish the histological
diagnosis and, if possible, the site within the oesophagus
and the length of the tumour. The most common end-
oscopic appearance of the tumour is a visible swelling
extending to a variable extent around the oesophageal
wall and down the length of the oesophagus. It may be
flat and plaque-like, or proliferative, reducing the lumen of
the oesophagus. This is followed by a CT scan of the chest
and abdomen to determine the presence of any local or
distal spread.
Differential diagnosis
As mentioned previously, oesophageal biopsies from in-
dividuals with tylosis do not have any specific distinct-
ive features [14]. It is the combination of family history
of both tylosis and oesophageal cancer, late onset skin
lesions (i.e. substantially after birth but before puberty) and,
more recently, the demonstration of mutation in RHBDF2
that enable differential diagnosis [12]. However care should
be taken to distinguish tylosis from other palmoplantar ker-
atodermas (PPKs). The PPKs are a heterogeneous collec-
tion of skin disorders characterised by abnormal thickening
of the skin of the volar surfaces of the hands and feet. They
can be divided clinically into diffuse, focal and punc-
tate types, histologically into epidermolytic and non-
epidermolytic types and into hereditary and acquired
types. Further subdivisions into simple (involvement of
the palms and soles only), complex (involvement of
non-volar skin including its appendages and, in certain
cases, the buccal mucosa) and syndromic (associated
with abnormalities in other bodily systems) are also
made [15]. Diffuse epidermolytic PPK (EPPK) has been
shown to be due to mutations in the gene encoding
the palmoplantar specific keratin, KRT9, and in some
cases KRT1 (16) whilst diffuse, non-epidermolytic PPK
(NEPPK) has recently been associated with mutations
in the gene encoding the water channel protein, Aqua-
porin 5 [17]. In focal PPK, the hyperkeratosis is less
extensive and restricted to areas of weight bearing
and/or friction. There are several types of focal PPK
with abnormalities in other organs including hearing
loss [18] and cardiomyopathy [19] due to defective gap
junctions or desmosomes, respectively. Quite often the
focal PPKs are complex and associated with abnorma-
lities of the hair, nails, teeth and/or sweat glands par-
ticularly those associated with desmosomal mutations
[19]. Using high throughput sequencing platforms,
more genes underlying other forms of keratodermas
are also being identified [20].
Genetic counselling
Tylosis with oesophageal cancer is inherited as an auto-
somal dominant trait with complete penetrance. To date,
three disease-associated missense mutations in RHBDF2
have been identified: c.557 T→C (p.Ile186Thr), c.566C→
T (p.Pro189Leu) and c.562 G→A (p.Asp188Asn) [6, 12]
and form part of genetic counselling for the Liverpool
family.
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Management including treatment
The key management goal in patients with tylosis with
oesophageal cancer is surveillance for early detection and
treatment of oesophageal dysplasia. Since 1975, screening
of members of the Liverpool family has included annual
gastroscopy with biopsy of any suspicious lesion (Fig. 2)
and quadratic biopsies (four biopsies equally spaced apart
at any particular level) from the upper, middle and lower
oesophagus to identify dysplasia. In the Liverpool family, it
is recommended to start upper gastrointestinal (GI) endos-
copy surveillance from the early twenties because one of
the family members developed cancer at that age. In order
to try and improve the sensitivity of the oesophageal sur-
veillance, other endoscopic modalities have been tried, in-
cluding narrow band imaging, but this did not result in
earlier identification of precancerous lesions [21]. Further
research is ongoing using chromoendoscopy (Smart HL,
personal communication) during which a 20 % solution
of iodine is sprayed via a cannula onto the wall of the
oesophagus (Fig. 3). Areas of dysplasia and actual tumour
show up as pale areas where the iodine dye has not been
taken up by the oesophageal epithelium.
In addition to surveillance, all patients are given diet and
lifestyle modification advice including smoking cessation
and alcohol restriction, both of which are known risk fac-
tors for OSCC [22]. It is not known whether smoking and/
or alcohol consumption are risk factors for oesophageal
cancer development in individuals with tylosis because of
the small number of patients, but it is likely that they are.
Patients are encouraged to eat fresh fruit and vegeta-
bles [23] and are educated regarding the symptoms of
oesophageal carcinoma such as dysphagia, odynopha-
gia, anorexia and weight loss.
Symptomatic management of the tylosis includes regu-
lar application of emollients, specialist footwear and early
treatment of fissures and super-added infection, particu-
larly tinea pedis. More specific treatment for the thick skin
is available in the form of oral retinoid tablets such as
Etretinate and Acitretin. These treatments can be effective
in causing the thick skin to regress but unfortunately side
effects are common including nasal excoriation and bleed-
ing, hyperlipidaemia, and abnormal liver function tests.
Sporadic oesophageal cancer usually presents in mid-
dle to late life (from mid-fifties onwards) as does the
oesophageal cancer associated with tylosis, apart from
the single exception mentioned above. If the tumour is
deemed resectable then the treatment is surgery. If it is
not resectable, then radiotherapy with or without chem-
otherapy is used. Local measures such as the insertion of a
mesh stent may be employed depending on the size of the
tumour to enable the patient to swallow while waiting treat-
ment or if only palliative treatment is required.
Prognosis
The prognosis of tylosis with oesophageal cancer is diffi-
cult to determine due to the limited number of affected
individuals. Many of the oesophageal cancers in the Liv-
erpool family occurred in earlier generations, however
between 1975 and 2014, while the screening program has
been operational, seven cases of squamous oesophageal
cancer were reported. One of these patients had declined
surveillance endoscopy and presented with an inoperable
tumour (stage 4). Of the remaining six cases, five were
detected during endoscopic screening while one presented
with stage 3 disease between surveillance endoscopies,
was surgically resected but died of disease. Four out of
five cases were detected with stage 1 disease during screen-
ing and survived 8, 8, 8 and 29 years following resection,
while the remaining tumour was detected as stage 3 dis-
ease with the patient dying of disease following resection.
Prognosis of OSCC depends greatly on stage with over-
all being poor (5-yr survival: <5 %) because at least 65 %
of patients usually present with stage 2–4 disease which
has already spread at least to regional lymph nodes. Our
current data, albeit on only seven patients with cancer,
suggests that the presence of a screening program im-
proves prognosis for the Liverpool family members by
detecting early stage disease. Patients with cancer restricted
to the mucosa (stage 1) have about an 80 % survival rate,
which drops to <50 % with submucosal involvement, 20 %
with extension to the muscularis propria, 7 % with exten-
sion to adjacent structures (stage 3), and <3 % with distant
metastases (stage 4).
Unresolved questions
Key questions include those based around the role for
iRhom2, encoded by RHBDF2, in keratinocyte and
Fig. 2 Dysplastic oesophageal lesion in tylosis with oesophageal
cancer. Dysplastic area (arrowed) identified in a 57 year old male
member of the Liverpool tylosis with oesophageal cancer family
during routine screening
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oesophageal biology. iRhom2 has been shown to regulate
the trafficking and activation of ADAM17, a membrane
bound sheddase which has been shown to play a pivotal
role in the cleavage and release of membrane bound TNFα
and EGFR ligands [24, 25]. Tylosis with oesophageal cancer
is associated with gain-of-function mutations in the highly
conserved cytoplasmic N-terminus of iRhom2 [6, 12]. As a
consequence of increased ADAM17 activity, tylosis-derived
keratinocytes show several features of “constitutive wound
healing” in vitro, including rapid closure in scratch-wound
assay, and upregulated shedding of ADAM17-dependent
substrates such as EGFR-family ligands and TNFα [13].
EGFR pathway dysregulation has been implicated in several
epithelial malignancies including sporadic squamous cell
carcinoma of the oesophagus [26] and head and neck can-
cers [27]. It is likely that enhanced EGFR activity and TNFα
shedding observed in tissue from patients with tylosis with
oesophageal cancer facilitates tumourigenesis through aber-
rant and exaggerated wound healing, in response to stress
within the oesophagus. This implies that lifestyle alterations
to reduce physical or chemical damage to the oesophagus
epithelium may lead to a reduction in cancer incidence in
these individuals, although chemoprevention is also a clin-
ical goal.
Conclusions
Tylosis with oesophageal cancer is a rare, familial form of
squamous cell oesophageal cancer that does not demon-
strate early presentation. Identification of affected family
members and initiation of a surveillance program for early
detection may improve prognosis in these individuals. The
identification of a causative gene allows the introduction
of genetic screening into the diagnostic arena and paves
the way for functional studies with the possibility of pre-
ventative therapies.
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